Abcam, ab257102, Human SAA1 knockout A549 cell lysate

Size: 1Kit
SAA1 KO cell lysate available now. KO validated by. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 137 bp insertion in exon3 and 1 bp insertion in exon3.
Key facts
Cell type:A549,
Species or organism:Human,
Tissue:Lung,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, 137 bp insertion in exon3 and 1 bp insertion in exon3.,
Disease:Carcinoma

Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-SAA1, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Serum amyloid A1 (SAA1) is a small protein with a molecular mass of approximately 12 kDa. Researchers also call it SAA or acute phase serum amyloid protein. Hepatocytes mainly express SAA1 during the acute phase response but some expression occurs in other tissues. SAA1 significantly increases in response to inflammatory stimuli acting as an important player in the body's reaction to injury or infection.
Biological function summary
This protein regulates cholesterol metabolism and serves as a chemoattractant directing cell movement towards the sites of inflammation. SAA1 does not exist alone often associating with high-density lipoproteins (HDL) in circulation. By binding to HDL it can aid in transporting cholesterol from tissues to the liver for excretion linking it with both immunological and metabolic processes.
Pathways
Researchers place SAA1 within the inflammation and immune response strategies. It significantly contributes to the acute-phase response and relates to cytokine signaling pathways. SAA1 interacts with proteins such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) which are central to the activation and propagation of inflammatory responses in tissues.
SAA1 closely associates with chronic inflammatory conditions and amyloidosis. Excessive SAA1 levels can lead to amyloid A (AA) amyloidosis where protein fragments deposit abnormally in organs. It also plays a role in conditions like rheumatoid arthritis where inflammation perpetuates disease progression. Interestingly SAA1 levels correlate with C-reactive protein (CRP) another marker of inflammation frequent in similar disorders.